Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study
Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectiveness and safety, suitable for analyses of daily pract...
Saved in:
Main Authors: | Juul M.P.A. van den Reek (Author), Lieke J. van Vugt (Author), Martijn B.A. van Doorn (Author), Gayle E. van der Kraaij (Author), Wim J.A. de Kort (Author), Georges P.H. Lucker (Author), Barbara Horvath (Author), M. David Njoo (Author), H. Jorn Bovenschen (Author), Paul M. Ossenkoppele (Author), Marjolein S. De Bruin-Weller (Author), Marjan de Groot (Author), Roland Mommers (Author), Ruud L.M.A. Prevoo (Author), Peter C.M. van de Kerkhof (Author), Phyllis I. Spuls (Author), Wietske Kievit (Author), Elke M.G.J. de Jong (Author) |
---|---|
Format: | Book |
Published: |
Medical Journals Sweden,
2018-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
by: Selma Atalay, et al.
Published: (2020) -
Beliefs About Medicines in Patients with Psoriasis Treated with Methotrexate or Biologics: A Cross-sectional Survey Study
by: Marisol E. Otero, et al.
Published: (2019) -
Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice
by: Selma Atalay, et al.
Published: (2021) -
Global Risk of Bacterial Skin Infections and Herpesviridae Infections with Ustekinumab, Secukinumab, and Tumour Necrosis Factor-alpha Inhibitors: Spontaneous Reports of Adverse Drug Reactions from the World Health Organization Pharmacovigilance Center
by: Linda Davidson, et al.
Published: (2022) -
Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
by: Marloes E. van Muijen, et al.
Published: (2022)